CHA Vaccine Institute Co. Ltd.
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in p… Read more
CHA Vaccine Institute Co. Ltd. (261780) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.140x
Based on the latest financial reports, CHA Vaccine Institute Co. Ltd. (261780) has a cash flow conversion efficiency ratio of -0.140x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.46 Billion) by net assets (₩17.56 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CHA Vaccine Institute Co. Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how CHA Vaccine Institute Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CHA Vaccine Institute Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CHA Vaccine Institute Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
-0.143x |
|
Jagsonpal Pharmaceuticals Limited
NSE:JAGSNPHARM
|
0.098x |
|
Ray Co. Ltd
KQ:228670
|
0.053x |
|
Jaanh CosmeticsInc.
KQ:219550
|
-0.295x |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
-0.020x |
|
ONDE S.A. ZY -02
F:0XF
|
N/A |
|
Singapore Shipping Corporation Limited
F:W1M
|
0.034x |
|
Sewoon Medical Co. Ltd
KQ:100700
|
0.033x |
Annual Cash Flow Conversion Efficiency for CHA Vaccine Institute Co. Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of CHA Vaccine Institute Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩27.72 Billion | ₩-8.10 Billion | -0.292x | -95.39% |
| 2023-12-31 | ₩35.42 Billion | ₩-5.29 Billion | -0.149x | +3.89% |
| 2022-12-31 | ₩33.37 Billion | ₩-5.19 Billion | -0.156x | -29.98% |
| 2021-12-31 | ₩39.61 Billion | ₩-4.74 Billion | -0.120x | +95.24% |
| 2020-12-31 | ₩1.57 Billion | ₩-3.95 Billion | -2.514x | -817.28% |
| 2019-12-31 | ₩-8.83 Billion | ₩-3.09 Billion | 0.350x | -- |